USF-LVHN SELECT
Advancements in biologic therapy in eosinophilic asthma.
Publication/Presentation Date
4-15-2024
Abstract
INTRODUCTION: Asthma encompasses a spectrum of phenotypes often categorized into two groups- type 2 high (T2 high) and type 2 low (T2 low). T2 high includes atopic and eosinophilic presentations whereas T2 low is non-atopic, non-eosinophilic, and oft associated with neutrophilic inflammation. Eosinophilic asthma is often driven by IgE, IL-4, IL-5, and IL-13 and TSLP. This can lead to eosinophilic inflammatory response in the airways which in turn can be used as target for treatment.
AREAS COVERED: The article will focus on biologic therapy that is currently being used in eosinophilic asthma management in mainly the adult population including clinical trials and co-morbidities that can be treated using the same biologics. A review on asthma biologics for pediatric population has been reviewed elsewhere.
EXPERT OPINION: Biological therapy for asthma targeting the IgE, IL-4, IL-5, IL-13, and TSLP pathways are shown to have benefit for the treatment of eosinophilic asthma, as exemplified in real world studies. When choosing the right biological agent factors such as phenotype, comorbidities, and cost-effectiveness of the biologic agent must be taken into consideration.
ISSN
1744-7682
Published In/Presented At
Patadia, R., Casale, T. B., Fowler, J., Patel, S., & Cardet, J. C. (2024). Advancements in biologic therapy in eosinophilic asthma. Expert opinion on biological therapy, 10.1080/14712598.2024.2342527. Advance online publication. https://doi.org/10.1080/14712598.2024.2342527
Disciplines
Medical Education | Medicine and Health Sciences
PubMedID
38619468
Department(s)
USF-LVHN SELECT Program, USF-LVHN SELECT Program Students
Document Type
Article